Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Several other research firms also recently commented on AUPH. Leerink Swann boosted their price objective on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. HC Wainwright restated a “buy” rating and set a $12.00 price objective (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a report on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Finally, Royal Bank of Canada assumed coverage on Aurinia Pharmaceuticals in a report on Thursday. They set an “outperform” rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $10.59.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals’s revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its holdings in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,341 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after buying an additional 26,395 shares in the last quarter. Spark Investment Management LLC bought a new stake in Aurinia Pharmaceuticals during the fourth quarter worth $153,000. Cutler Capital Management LLC grew its holdings in Aurinia Pharmaceuticals by 33.3% during the third quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after buying an additional 10,000 shares in the last quarter. Finally, Investment Centers of America Inc. grew its holdings in Aurinia Pharmaceuticals by 100.0% during the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 27.96% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/12/aurinia-pharmaceuticals-auph-stock-rating-upgraded-by-zacks-investment-research.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.